Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.73 |
| ▸ | PDE7B | Q9NP56 | 2/20 | 0.73 |
| ▸ | HTT | P42858 | 2/20 | 0.72 |
| ▸ | CA12 | O43570 | 4/20 | 0.69 |
| ▸ | CA1 | P00915 | 4/20 | 0.69 |
| ▸ | CA2 | P00918 | 4/20 | 0.69 |
| ▸ | CA9 | Q16790 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.53 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30103233 | 0.85 | PDE7A (1.00) | ALDH1A1RXFP1L3MBTL1PDE7APDE7B | |
| SCHEMBL844588 | 0.85 | PDE7A (1.00) | ALDH1A1RXFP1L3MBTL1PDE7APDE7B | |
| SCHEMBL9955792 | 0.84 | ALDH1A1 (0.73) | ALDH1A1RXFP1L3MBTL1PDE7APDE7B | |
| SCHEMBL3336450 | 0.83 | ALDH1A1 (0.71) | ALDH1A1RXFP1L3MBTL1PDE7APDE7B | |
| SCHEMBL23045531 | 0.83 | ALDH1A1 (0.71) | ALDH1A1RXFP1L3MBTL1PDE7APDE7B | |
| SCHEMBL9954144 | 0.83 | ALDH1A1 (0.71) | ALDH1A1RXFP1L3MBTL1PDE7APDE7B | |
| SCHEMBL31597545 | 0.83 | ALDH1A1 (0.71) | ALDH1A1RXFP1L3MBTL1PDE7APDE7B | |
| SCHEMBL9954310 | 0.81 | CA12 (0.70) | ALDH1A1RXFP1L3MBTL1PDE7APDE7B | |
| SCHEMBL9953988 | 0.80 | CA12 (0.68) | ALDH1A1RXFP1L3MBTL1PDE7APDE7B | |
| SCHEMBL9953957 | 0.80 | ALDH1A1 (0.67) | ALDH1A1RXFP1L3MBTL1PDE7APDE7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152213-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-06-17 | — | — | US | claimed |
| EP-2130823-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Consejo Superior De Investigaciones Científicas (ES) | 2009-12-09 | — | — | EP | claimed |
| WO-2012087938-A1 | QUINAZOLINONE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087938-A1 | QUINAZOLINONE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20100152213-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-06-17 | — | — | US | disclosed |
| US-20100152213-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-06-17 | — | — | US | disclosed |
| US-20100152213-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-06-17 | — | — | US | disclosed |
| EP-2130823-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Consejo Superior De Investigaciones Científicas (ES) | 2009-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152213-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | PDE4B, PDE7B, PDE12 | ALDH1A1 826/4885RXFP1 1252/4885L3MBTL1 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.